https://www.selleckchem.com/products/mhy1485.html
Patients with severe mental illness (SMI) have a high risk for diabetes, dyslipidemia, and other components of metabolic syndrome. Patients with these metabolic comorbidities and cardiac risk factors should receive not only antipsychotics but also medications aiming to reduce cardiovascular risk. Therefore, many patients may be exposed to clinically relevant drug-drug interactions. This narrative review summarizes data regarding the known or potential drug-drug interactions between antipsychotics and medications treating metabolic syndr
Like
Comment
Share
